With over one billion people worldwide affected by obesity, the weight-loss drug market is hot. In 2024, the global market for anti-obesity medications (AOMs) surpassed $30 billion for the first time, marking a tenfold increase since 2020. These medications are transforming the healthcare landscape, offering new solutions for the 40% of U.S. adults classified as obese.
So, with billions in potential sales and an increasingly crowded field, it could be an opportune time for investors to scoop up the shares of companies like Eli Lilly and Company (LLY), Novo Nordisk A/S (NVO), and Amgen Inc. (AMGN), which are doubling down on their efforts to dominate this high-growth sector.
